Physician profile
Thomas E Smallwood
NPI 1386644938
$5,782.68
in general payments reported to CMS, 2019-2025
44 companies · $1,446 in 2025
The $1,446 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $513 · 2021: $568 · 2022: $799 · 2023: $961 · 2024: $825 · 2025: $1,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,190 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,190.06 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,103.37 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Pfizer INC. | $530.88 | 2019-2024 | |
| Novo Nordisk INC | $348.12 | 2020-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $277.05 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $268.77 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $248.25 | 2023-2024 | Rexulti, Nuedexta |
| Lundbeck LLC | $238.76 | 2023-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $213.94 | 2024-2025 | Fanapt, Hetlioz |
| Novartis Pharmaceuticals Corporation | $208.81 | 2019-2021 | |
| Abbott Laboratories | $186.21 | 2021-2025 | Freestyle Libre 3, Mitraclip, Freestyle Libre 2 |
| Neurocrine Biosciences, INC. | $174.17 | 2023-2025 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.39 | 2019-2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $157.12 | 2019-2022 | |
| Abbvie INC. | $143.92 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $140.64 | 2019-2020 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $119.15 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $109.16 | 2022-2025 | Zoryve, Seglentis |
| Exact Sciences Corporation | $107.88 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $101.75 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $89.14 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.85 | 2019-2022 | |
| Biogen, INC. | $82.75 | 2020-2021 | |
| Dexcom, INC. | $73.76 | 2022-2024 | Dexcom G6 Transmitter |
| Organogenesis INC. | $72.66 | 2021 | |
| Sunovion Pharmaceuticals INC. | $64.57 | 2019 | |
| Amgen INC. | $59.80 | 2019-2022 | |
| Mannkind Corporation | $54.54 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.58 | 2021-2022 | |
| Bausch Health US, LLC | $32.97 | 2022 | |
| Daiichi Sankyo INC. | $30.62 | 2019-2022 | |
| Almatica Pharma LLC | $29.35 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $28.26 | 2019 | |
| Allergan, INC. | $23.26 | 2019-2020 | |
| Ucb, INC. | $20.06 | 2022 | |
| Indivior INC. | $15.95 | 2021 | |
| Corcept Therapeutics | $15.95 | 2025 | Korlym |
| Alkermes, INC. | $15.62 | 2024 | Aristada, Lybalvi |
| Advanced Respiratory, INC | $15.46 | 2021 | |
| Shield Therapeutics INC | $14.49 | 2024 | |
| Eisai INC. | $14.19 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.30 | 2023 | Eliquis |
| Arbor Pharmaceuticals, INC. | $12.50 | 2021 | |
| Astellas Pharma US INC | $12.47 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Smallwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.